While there are sporadic case reports of secukinumab improving a patient with autosomal recessive congenital ichthyosis harboring an ABCA12 variant [45], as well as patients with Netherton’s syndrome [46, 47], a double-blind randomized controlled trial evaluating secukinumab in 4 types of CI patients compared to placebo failed to reduce disease severity or reduce Th17-related biomarkers [48]. This evidence concerns the gene ABCA12 and autosomal recessive congenital ichthyosis.